The hope and reality of long-acting hemophilia products.

@article{Pipe2012TheHA,
  title={The hope and reality of long-acting hemophilia products.},
  author={Steven W Pipe},
  journal={American journal of hematology},
  year={2012},
  volume={87 Suppl 1},
  pages={S33-9}
}
Recombinant DNA technology and protein engineering are creating hope that we can address ongoing challenges in hemophilia care such as reducing the costs of therapy, increasing the availability to the developing world, and improving the functional properties of these proteins. Technological advances to improve the half-life of recombinant clotting factors have brought long-acting clotting factors for hemophilia replacement therapy closer to reality. Preclinical and clinical trial results are… CONTINUE READING